Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077012 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
A Phase 1 study, sponsored by QLT.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00077012: Completed Phase 1 study, sponsored by QLT.
NCT00077012 is a Phase 1 study that has completed, run by QLT. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077012, a Phase 1 study, has completed, sponsored by QLT.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The primary objective of this study is to assess the safety and tolerance of transurethral photodynamic therapy (PDT) with QLT0074. Secondary objectives are: 1. To determine if transurethral PDT with QLT0074 has a therapeutic effect on benign prostatic hyperplasia (BPH), evaluated by the American Urological Association Symptom Index (AUA SI), urinary flow rate (Qmax), and post-void residual volume (PVR). 2. To determine the extent of systemic exposure to QLT0074 following transurethral intraprostatic injection. 3. To select up to two transurethral PDT drug-light regimens for further clinical development.
Interventions
- DRUG QLT0074
- DRUG Photodynamic therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-03 |
| Est. Completion | 2005-05 |
| Phase | Phase 1 |
What the finished NCT00077012 record still lists
NCT00077012 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which QLT0074 is the first listed.
NCT00077012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00077012 about?
NCT00077012 is a clinical study titled "Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia". The primary objective of this study is to assess the safety and tolerance of transurethral photodynamic therapy (PDT) with QLT0074. Secondary objectives are: 1. To determine if transurethral PDT with QLT0074 has a therapeutic effect on benign prostatic hyperplasia (BPH), evaluated by the American ...
What is the current status of trial NCT00077012?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-03. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00077012?
The interventions under investigation include: QLT0074 (DRUG), Photodynamic therapy (DRUG).
Who is sponsoring clinical trial NCT00077012?
This trial is sponsored by QLT, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia